These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [Denosumab as the potent therapeutic agent against Paget's disease of bone]. Hirao M; Hashimoto J Clin Calcium; 2011 Aug; 21(8):1231-8. PubMed ID: 21814030 [TBL] [Abstract][Full Text] [Related]
43. Denosumab for joints and bones. Lewiecki EM Curr Rheumatol Rep; 2009 Jul; 11(3):196-201. PubMed ID: 19604464 [TBL] [Abstract][Full Text] [Related]
44. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA; J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711 [TBL] [Abstract][Full Text] [Related]
45. Denosumab, osteoporosis, and prevention of fractures. Kyrgidis A N Engl J Med; 2009 Nov; 361(22):2189; author reply 2190-1. PubMed ID: 19950409 [No Abstract] [Full Text] [Related]
47. Denosumab in postmenopausal women with low bone mineral density. Rifkin WD N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16742010 [No Abstract] [Full Text] [Related]
48. Denosumab for the treatment of postmenopausal osteoporosis. Lewiecki EM Womens Health (Lond); 2009 Jan; 5(1):15-22. PubMed ID: 19274891 [No Abstract] [Full Text] [Related]
49. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Anastasilakis AD; Toulis KA; Goulis DG; Polyzos SA; Delaroudis S; Giomisi A; Terpos E Horm Metab Res; 2009 Oct; 41(10):721-9. PubMed ID: 19536731 [TBL] [Abstract][Full Text] [Related]
50. New therapeutical horizons in the management of postmenopausal osteoporosis. Migliaccio S; Fornari R; Greco EA; Di Luigi L; Lenzi A Aging Clin Exp Res; 2013 Oct; 25 Suppl 1():S117-9. PubMed ID: 24048905 [TBL] [Abstract][Full Text] [Related]
52. [Bone remodeling: new therapeutic approaches]. Ferrari S Rev Med Suisse; 2009 Jun; 5(207):1325-8. PubMed ID: 19626933 [TBL] [Abstract][Full Text] [Related]
53. Denosumab for the treatment of osteoporosis. Iqbal J; Sun L; Zaidi M Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349 [TBL] [Abstract][Full Text] [Related]
55. [Animal models for bone and joint disease. RANKL-injected bone loss model]. Yasuda H Clin Calcium; 2011 Feb; 21(2):197-208. PubMed ID: 21289416 [TBL] [Abstract][Full Text] [Related]
56. Denosumab, osteoporosis, and prevention of fractures. Kiechl S; Willeit J; Schett G N Engl J Med; 2009 Nov; 361(22):2188-9; author reply 2190-1. PubMed ID: 19940304 [No Abstract] [Full Text] [Related]
57. Denosumab in postmenopausal women with low bone mineral density. Schwartzman J; Yazici Y N Engl J Med; 2006 Jun; 354(22):2390-1; author reply 2390-1. PubMed ID: 16738280 [No Abstract] [Full Text] [Related]
59. [Anti-RANKL antibody for the management of bone metastasis]. Yoneda T Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338 [TBL] [Abstract][Full Text] [Related]
60. Denosumab. Limited efficacy in fracture prevention, too many adverse effects. Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]